Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Pneumovax 23 Market Revenue Outlook: What CAGR Is Expected Through 2030?
The historic period’s expansion was driven by the broadening of national immunization guidelines, a growing prevalence of pneumococcal infections among older adults, the accessibility of polysaccharide vaccines, the strengthening of preventive healthcare efforts, and heightened public awareness regarding vaccination.
Rising investment in adult vaccination initiatives and a greater emphasis on preventing infectious diseases have driven growth in the forecast period, alongside the expansion of pharmacy-based immunization services, increasing demand for long-lasting vaccine protection, and improvements in vaccine storage and distribution. Key trends shaping this period include a heightened focus on immunization programs targeting adults and the elderly, growing need for pneumococcal disease prevention, wider adoption of preventive vaccination approaches, the scale-up of public health immunization campaigns, and better cold-chain management for vaccines.
Download A Free Sample Report For Comprehensive Market Insights:
Pneumovax 23 Market Expansion Drivers: What Is Shaping Future Growth?
The rising occurrence of pneumococcal diseases is set to fuel the expansion of the pneumovax 23 market moving forward. These diseases, triggered by the bacterium streptococcus pneumoniae, also referred to as pneumococcus, can cause a spectrum of health problems ranging from mild conditions like sinusitis and otitis media to serious illnesses such as pneumonia and meningitis, which may necessitate hospital care. This uptick in pneumococcal disease cases is linked to elements like diminished vaccination rates during the COVID-19 pandemic, elevated susceptibility among those with chronic conditions, and a rebound in respiratory infections after social distancing measures were lifted. By immunizing against 23 strains of streptococcus pneumoniae, pneumovax 23 lowers the chances of infections including pneumonia, meningitis, and bacteremia. As an illustration, the Office for Health Improvement and Disparities, a UK government entity focused on public health and reducing health inequalities, noted in June 2025 that emergency hospital admissions for pneumonia in England during the financial year ending 2024 rose by 16% compared to the prior year, hitting a rate of 430 per 100,000 people and accounting for roughly 252,912 admissions. Consequently, the worldwide increase in pneumococcal disease incidence is propelling the growth of the pneumovax 23 market.
Pneumovax 23 Market Driver: Urbanization Drives Demand For Vaccine Amid Rising Global Population In Cities
An accelerated pace of urbanization is expected to steer the expansion of the pneumovax 23 market in the coming years. This trend is fueled by industrialization, which creates enhanced job prospects in cities, improved access to education and healthcare, and the overall appeal of metropolitan lifestyles that draw people from rural areas seeking a better quality of life. City dwellers often benefit from greater exposure to health education and awareness initiatives, which can boost vaccination uptake as the significance of preventing pneumococcal diseases becomes more recognized. For example, a report from the World Bank Group, a US-based financial institution, published in April 2023, indicated that approximately 56% of the global population, or 4.4 billion individuals, reside in urban zones—a pattern anticipated to persist, with the urban populace projected to nearly double by 2050, reaching close to 70%. Moreover, urban land consumption is outstripping population growth by as much as 50%, with an estimated 1.2 million square kilometers of new urban area set to be added by 2030. Hence, the growing rate of urbanization is fostering the growth of the pneumovax 23 market.
Pneumovax 23 Market Driver: Government Immunization Initiatives Driving Growth In The Market
The broadening of government-led immunization programs is anticipated to drive progress in the pneumovax 23 market going ahead. These initiatives, orchestrated by national or local authorities, aim to promote and deliver vaccines to populations to avert diseases preventable by vaccination, enhance coverage rates, and improve public health results through strategies such as routine immunization schedules, targeted vaccination drives, and awareness campaigns. This expansion is fueled by the necessity to strengthen public health outcomes, close immunization gaps that have arisen from events like the COVID-19 pandemic, and guarantee fair vaccine access for all groups to curb the spread of infectious diseases. Government immunization efforts boost pneumovax 23 usage by improving vaccine availability, raising public knowledge, and promoting higher vaccination levels to ward off pneumococcal conditions. By way of instance, in July 2024, Gavi, a vaccine alliance headquartered in Switzerland, reported that roughly 69 million children received routine immunizations backed by Gavi in 2023, nearing the record annual highs. As of 2024, over 72 million children in lower-income nations were vaccinated with Gavi support, indicating sustained expansion. Thus, the widening of government immunization initiatives is advancing the growth of the pneumovax 23 market.
Pneumovax 23 Market Segment Analysis: What Are The Major Market Categories?
The pneumovax 23 market covered in this report is segmented –
1) By Formulation: Pneumococcal Polysaccharide Vaccine (PPV), Pneumococcal Conjugate Vaccine (PCV)
2) By Clinical Indication: Pneumococcal Disease Prevention
3) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies
Pneumovax 23 Market Leading Companies Driving Competitive Growth
Major companies operating in the pneumovax 23 market are Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
Access The Complete Pneumovax 23 Market Report:
Pneumovax 23 Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the pneumovax 23 market in 2025. The regions covered in the pneumovax 23 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model